Lidds AB Total Liabilities
Lidds AB total liabilities. Based on the latest financial reports, Lidds AB (LIDDS) has total liabilities worth Skr491.00K SEK (≈ $52.84K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Lidds AB liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Lidds AB (2010–2024)
Total liabilities of Lidds AB from 2010 to 2024. This chart illustrates how Lidds AB's total liabilities have evolved over time, based on quarterly financial data. Explore LIDDS strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Lidds AB Competitors by Total Liabilities
The table below lists competitors of Lidds AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Israel Opportunity - Energy Resources LP
TA:ISOP-L
|
Israel | ILA259.00K |
|
Wildpack Beverage Inc
V:CANS
|
Canada | CA$141.24 Million |
|
SysGroup PLC
LSE:SYS
|
UK | GBX14.56 Million |
|
Helium One Global Ltd
LSE:HE1
|
UK | GBX1.26 Million |
|
KOYJ Co. Ltd
KQ:121850
|
Korea | ₩20.66 Billion |
|
BLUERUSH Media Group Corp
V:BTV
|
Canada | CA$7.19 Million |
|
Imobiliária Construtora Grão Pará S.A.
LS:GPA
|
Portugal | €27.13 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Lidds AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see LIDDS current and non-current assets.
Liquidity & Leverage Metrics
Lidds AB Total Liabilities Ratios Explained
Lidds AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 3.53 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lidds AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lidds AB (2010–2024)
The table below shows the annual total liabilities of Lidds AB from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr1.98 Million ≈ $212.97K |
-47.31% |
| 2023-12-31 | Skr3.76 Million ≈ $404.21K |
-64.47% |
| 2022-12-31 | Skr10.57 Million ≈ $1.14 Million |
+49.58% |
| 2021-12-31 | Skr7.07 Million ≈ $760.52K |
-37.99% |
| 2020-12-31 | Skr11.40 Million ≈ $1.23 Million |
+91.05% |
| 2019-12-31 | Skr5.96 Million ≈ $641.91K |
+22.76% |
| 2018-12-31 | Skr4.86 Million ≈ $522.91K |
+36.48% |
| 2017-12-31 | Skr3.56 Million ≈ $383.16K |
-58.06% |
| 2016-12-31 | Skr8.49 Million ≈ $913.69K |
+229.98% |
| 2015-12-31 | Skr2.57 Million ≈ $276.89K |
+10.96% |
| 2014-12-31 | Skr2.32 Million ≈ $249.55K |
+47.07% |
| 2013-12-31 | Skr1.58 Million ≈ $169.68K |
-55.24% |
| 2012-12-31 | Skr3.52 Million ≈ $379.11K |
+107.08% |
| 2011-12-31 | Skr1.70 Million ≈ $183.08K |
+42.38% |
| 2010-12-31 | Skr1.19 Million ≈ $128.59K |
-- |
About Lidds AB
LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemoth… Read more